학술논문
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
Document Type
Article
Author
Source
In The Lancet 8-14 January 2022 399(10320):161-171
Subject
Language
ISSN
0140-6736